Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.

Dmitry V Shcheblyakov, Anna V Kovyrshina + Show 14 more

Open Access

https://doi.org/10.3389/fimmu.2023.1259725

Copy DOI

Journal: Frontiers in immunology	Publication Date: Oct 20, 2023
License type: CC BY 4.0

Abstract

https://clinicaltrials.gov/, identifier NCT05982704.

Full Text

Published version (

Free)

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Paper Title

Journal

Date

Author

Paper Title

Journal

Date

Author